HC Wainwright & Co. Reiterates Buy on G1 Therapeutics, Maintains $11 Price Target
Portfolio Pulse from richadhand@benzinga.com
HC Wainwright & Co. analyst Edward White has reiterated a 'Buy' rating on G1 Therapeutics (NASDAQ:GTHX) and maintained an $11 price target.
August 04, 2023 | 12:45 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
G1 Therapeutics (NASDAQ:GTHX) has been reiterated with a 'Buy' rating by HC Wainwright & Co. The price target remains at $11.
The 'Buy' rating from HC Wainwright & Co. indicates a positive outlook for G1 Therapeutics. The maintained price target of $11 suggests that the analyst believes the stock has potential for growth. This could lead to increased investor interest and potentially a rise in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100